Starling Oncology, Inc. (STLNW) stock

STLNWNasdaqServices-Offices & Clinics of Doctors of MedicineFiscal year ends December 31Also trades as DFPH, STLN

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 6/30

$0.03+0.00 (+10.87%)

Close on Oct 30, 2026Market cap $665.51MP/E –Yield –

Starling Oncology price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Starling Oncology's price to sales ratio was 1.1× on Oct 19, 2026, against 1.0× a year earlier. Over the last 5 years it ranged from 0.0× to 3.2×, with a median of 0.5×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Oct 19, 2026	1.1×	+0.4
2025	Dec 31, 2025	0.8×	+0.7
2024	Dec 31, 2024	0.1×	−0.4
2023	Dec 29, 2023	0.5×	−0.0
2022	Dec 30, 2022	0.5×	–

Where these numbers come from

Parsed from the XBRL in Starling Oncology's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is STLNW.

Compare: STLNW vs CCM · STLNW vs SBC · STLNW vs LFMD · STLNW vs TDOC · STLNW vs AUNA

Revenue growth38.4% · median -2.4%

Operating margin-4.4% · median -6.6%

Net margin-6.2% · median 0.1%

Company	Revenue	Growth
TDOC	$2.47B	-2.4%
STLNW	$587.24M	+38.4%
SBC	$175.17M	-6.9%
LFMD	$164.70M	+3.8%
CCM	–	–
AUNA	–	–

Company

Next earnings (est.): Nov 12, 2026, during market hours
Exchange: Nasdaq
Industry: Services-Offices & Clinics of Doctors of Medicine
Fiscal year ends: December 31
Employees: 641
Auditor: BDO USA, P.C.
SEC CIK: 1799191

Advertisement
300 × 250

Starling Oncology price to sales ratio

Price to Sales Ratio at the end of each year

More Starling Oncology figures